Cardiovascular risk factors, haemostasis and antithrombotic treatment in retinal vessel occlusion

被引:0
|
作者
Kuhli-Hattenbach, Claudia [1 ]
Sucker, Christoph [2 ,3 ]
Feltgen, Nicolas [4 ]
Spitzer, Martin [5 ]
Schultheiss, Maximilian [5 ]
Hattenbach, Lars-Olof [6 ]
机构
[1] Goethe Univ, Klin Augenheilkunde, Theodor Stern Kai 7, D-60590 Frankfurt, Germany
[2] Med Hsch Brandenburg MHB, Brandenburg, Germany
[3] COAGUMED Gerinnungszentrum, Med Versorgungszentrum MVZ, Berlin, Germany
[4] Univ Augenklin Gottingen, Gottingen, Germany
[5] Univ Klinikum Hamburg Eppendorf, Klin Augenheilkunde, Hamburg, Germany
[6] Klinikums Ludwigshafen, Augenklin, Ludwigshafen, Germany
来源
OPHTHALMOLOGIE | 2022年 / 119卷 / 11期
关键词
Retinal vein occlusion; Thrombophilic risk factors; Resistence to APC; Factor-XII-deficiency; Lipid metabolism; TISSUE-PLASMINOGEN ACTIVATOR; FACTOR-XII DEFICIENCY; VEIN OCCLUSION; ARTERY-OCCLUSION; PLATELET ACTIVATION; INTRAVENOUS THROMBOLYSIS; FIBRINOLYTIC THERAPY; HIGH PREVALENCE; PROTEIN-C; MULTICENTER;
D O I
10.1007/s00347-022-01751-y
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Venous and arterial retinal vascular occlusions are age-related disorders, generally associated with classical cardiovascular risk factors, rather than an isolated ocular disease. As affected patients often also have an increased general risk for other vascular diseases, such as ischemic stroke, an interdisciplinary clarification of cardiovascular risk factors and systemic comorbidities is essential for all patients. Extended hemostaseological investigations may be recommended in those patients who do not match the typical risk profile. Patients at a young age by the time of manifestation, without conventional risk factors as well as patients with an increased risk of developing antiphospholipid syndrome may require a selective clinical investigation including testing for thrombophilic risk factors. Recent studies have clearly demonstrated an association between coagulation and lipid metabolism disorders and the development of both retinal vein and artery occlusions in specific subgroups of patients. Therapeutic approaches to treat retinal vascular occlusions or reduce the long-term risk of recurrences with anticoagulant or antiplatelet drugs have not gained widespread acceptance. However, intravenous thrombolysis may be a valuable treatment option for central retinal artery occlusions within a short time to treatment therapeutic window. For defined disorders of the coagulation system, the administration of antithrombotic drugs to reduce the general vascular risk can be a reasonable approach. This article provides an overview of cardiovascular risk factors, the general vascular risk and the current state of knowledge on ophthalmologically relevant disorders of coagulation and lipid metabolism in patients with venous and arterial retinal vascular occlusions.
引用
收藏
页码:1129 / 1139
页数:11
相关论文
共 50 条
  • [41] Cardiovascular Risk Factors in Central Retinal Artery Occlusion Results of a Prospective and Standardized Medical Examination
    Callizo, Josep
    Feltgen, Nicolas
    Pantenburg, Stefanie
    Wolf, Armin
    Neubauer, Aljoscha Steffen
    Jurklies, Bernhard
    Wachter, Rolf
    Schmoor, Claudia
    Schumacher, Martin
    Junker, Bernd
    Pielen, Amelie
    OPHTHALMOLOGY, 2015, 122 (09) : 1881 - 1888
  • [42] Effects of Antithrombotic Agents on Ophthalmological Outcomes, Cardiovascular Risk, and Mortality in Hypertensive Patients with Retinal Vein Occlusion: An Exploratory Retrospective Study
    Bertoli, Federica
    Bais, Bruno
    De Silvestri, Daniele
    Mariotti, Barbara
    Veritti, Daniele
    Cavarape, Alessandro
    Catena, Cristiana
    Lanzetta, Paolo
    Sechi, Leonardo Alberto
    Colussi, GianLuca
    MEDICINA-LITHUANIA, 2021, 57 (10):
  • [43] Hypertension and multiple cardiovascular risk factors increase the risk for retinal vein occlusions: results from the Gutenberg Retinal Vein Occlusion Study
    Ponto, Katharina A.
    Scharrer, Inge
    Binder, Harald
    Korb, Christina
    Rosner, Ann K.
    Ehlers, Till O.
    Rieser, Nikola
    Grubel, Nadja C.
    Rossmann, Heidi
    Wild, Philipp S.
    Feltgen, Nicolas
    Pfeiffer, Norbert
    Mirshahi, Alireza
    JOURNAL OF HYPERTENSION, 2019, 37 (07) : 1372 - 1383
  • [44] Antithrombotic treatment for retinal vein occlusion: a systematic review and meta-analysis
    Valeriani, Emanuele
    Paciullo, Francesco
    Porfidia, Angelo
    Pignatelli, Pasquale
    Candeloro, Matteo
    Di Nisio, Marcello
    Donadini, Marco Paolo
    Mastroianni, Claudio Maria
    Pola, Roberto
    Gresele, Paolo
    Ageno, Walter
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2023, 21 (02) : 284 - 293
  • [45] Risk of Bleeding Related to Antithrombotic Treatment in Cardiovascular Disease
    Sorensen, Rikke
    Olesen, Jonas B.
    Charlot, Mette
    Gislason, Gunnar H.
    CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (33) : 5362 - 5378
  • [46] Prospective cohort study on cardiovascular risk in retinal vein occlusion
    Sartori, M. T.
    Dona, A.
    Piermarocchi, S.
    Pilotto, E.
    Saggiorato, G.
    Pagnan, A.
    Prandoni, P.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 1034 - 1034
  • [47] Childhood Vascular Risk Factors and Retinal Vessel Caliber
    Cheung, Ning
    Saw, Seang M.
    Liew, Gerald
    Liu, Erica Y.
    Hodgson, Lauren
    Mitchell, Paul
    Wong, Tien Y.
    ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY, 2012, 1 (04): : 193 - 197
  • [48] Thrombophilia and vascular risk factors in retinal vein occlusion
    Napa Lecumberri, J. J.
    Sedano Balbas, C.
    Canal Villanueva, J.
    Hernandez Hernandez, J. L.
    REVISTA CLINICA ESPANOLA, 2013, 213 (05): : 229 - 234
  • [49] Vascular risk factors for central retinal artery occlusion
    A K Rudkin
    A W Lee
    C S Chen
    Eye, 2010, 24 : 678 - 681
  • [50] RISK-FACTORS OF BRANCH RETINAL VEIN OCCLUSION
    JOHNSTON, RL
    BRUCKER, AJ
    STEINMANN, W
    HOFFMAN, ME
    HOLMES, JH
    ARCHIVES OF OPHTHALMOLOGY, 1985, 103 (12) : 1831 - 1832